ANXA2 and cancer: Healthy controls were not immunostained while the number of cases immunoreactive for ANXA2 steadily increased from the liver cirrhosis tissues (20/39, 51.3%) to the non-cancer (53/87, 60.9%) and cancer (68/87, 78.2%; Fig. 3) tissues.